Endpoints for Stopping Treatment in UC

Similar documents
Withdrawal of drug therapy in patients with quiescent Crohn s disease

September 12, 2015 Millie D. Long MD, MPH, FACG

IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants

Azathioprine for Induction and Maintenance of Remission in Crohn s Disease

Mono or Combination Therapy with. Individualized Approach

Common Questions in Crohn s Disease Therapy. Case

Optimizing the effectiveness of anti-tnf therapy in paediatric IBD

Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease

Highlights of DDW 2015: Crohn s disease

An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD

Anne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014

Update on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC

5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD

The Best of IBD at UEGW (Crohn s)

Biologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida

CCFA. Crohns Disease vs UC: What is the best treatment for me? November

Mucosal healing: does it really matter?

Medical Therapy for Pediatric IBD: Efficacy and Safety

Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy

Efficacy and Safety of Treatment for Pediatric IBD

Biologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College

Mucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium

Positioning Biologics in Ulcerative Colitis

IBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD

Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art

Il ruolo degli anticorpi anti farmaco nella pratica clinica

Definitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)

Achieving Success in Ulcerative Colitis: the Role of Infliximab

Personalized Medicine in IBD: Where Are We in 2013

Optimizing Immunomodulators and

Prevention and Management of Postoperative Crohn s disease

Indications for use of Infliximab

How to use infliximab?

Communicating with the IBD Patient: How to convey risks and benefits

To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,

Anti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis

Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals

Beyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center

Implementation of disease and safety predictors during disease management in UC

Predicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium

The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.

Extrapolation & Pediatric Development: A case study from pediatric Ulcerative Colitis Richard Strauss, MD

John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012

Efficacy and Safety of Treatment for Pediatric IBD

Medical Management of Inflammatory Bowel Disease

Lessons to learn from Crohn's disease clinical trials: implications for ulcerative colitis

Risk = probability x consequence

Recent Advances in the Management of Refractory IBD

Crohn s Disease: A New Approach to an Old Problem

Perianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic

Page 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis

Treatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10

Mild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested. Philippe Marteau, Paris, France

RE: Title: Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis

WHY HAVE WE NOT FINALLY FIGURED OUT COMBINATION THERAPY?

Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball

Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?

IBD Case Studies. David Rowbotham. Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital

Available Data on Pediatric Exposure Response a Clinician s Perspective

Crohn's Disease. The What, When, and Why of Treatment

Diagnostic and Therapeutic Approaches to Dysplasia in Inflammatory Bowel Diseases

INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL

Spectrum of Diverticular Disease. Outline

CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM

Once Daily Dosing for Induction and Maintenance of Remission in Ulcerative Colitis

5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA

Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts

Treatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG

Nutrition as primary therapy in IBD. Dr Clare Donnellan Leeds General Infirmary

Title: Author: Journal:

Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab.

Ali Keshavarzian MD Rush University Medical Center

Immunogenicity of Biologic Agents and How to Prevent Sensitization

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010

NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente

How to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009

Chromoendoscopy - Should It Be Standard of Care in IBD?

PEDIATRIC INFLAMMATORY BOWEL DISEASE

Optimizing the treatment of IBD through use of therapeutic drug monitoring

Drug Level Monitoring in IBD. Objectives

AVX-470, an Orally Delivered Anti-TNF Antibody for Treatment of Acute Ulcerative Colitis: Results of a First-in- Human Trial

Agenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease

Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists

Review article: induction therapy for patients with active ulcerative colitis

The future of IBD therapeutic research

Personalized Medicine in IBD

Therapeutic Drug Monitoring και ΙΦΝΕ το 2018

Op#mizing)Management)in)IBD:) Mucosal)Healing)

Management of Moderate to Severe Ulcerative Colitis

Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease

Crohn's Disease. The What, When, and Why of Treatment

AAPS NBC 2016 IBD Symposium

Preventing post-operative recurrence

Studies on inflammatory bowel disease and functional gastrointestinal disorders in children and adults Hoekman, D.R.

Fibrotic complications of inflammatory bowel disease

Personalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment

Percent Cumulative. Probability. Penetrating. Inflammatory. Stricturing. Months Patients at risk N =

CASE DISCUSSION: The Patient with Dysplasia: Surgery or Active Surveillance? Noa Krugliak Cleveland, MD David T. Rubin, MD

Microscopic Colitis. Darrell S. Pardi, MD Inflammatory Bowel Disease Clinic Mayo Clinic

Transcription:

Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh

IBD CD and UC pts require long term treatment to maintain remission and prevent relapses Side effects which can be rare, yet serious Opportunistic infx, lymphomas, skin ca High cost Compliance at times is problematic

Correctly identifying pts who can deescalate therapy and do well is very important

Who Can we Stop Meds on? Easy Answer CURE

Who to Consider Stopping Meds Clinical remission Endoscopic remission Histologic remission Biomarker negative Deep remission No clear guidelines regarding correctly identifying UC pts who can stop/de-escalate treatment once they are in remission..

Keep Taking Medication Until Something Better Comes Along

Outline of presentation Review current data on stopping treatment in UC pts Focus Relapse rates Factors associated with relapse

Four Possible Scenarios Stop 5-ASAs Stop AZA/6MP Monotherapy! on no meds Continue anti-tnf Stop anti-tnf and continue AZA/6MP Stop BOTH meds (no data at present) Most data in Crohn s (less data in UC) 8

Stopping 5-ASA Ulcerative proctitis pts require topical 5-ASA First episode of mild ulcerative proctitis Topical 5-ASA x 6-8 wks No need for maintenance If ulcerative proctitis pts relapse >1/yr Continue topical 5-ASA nightly

Stopping 5-ASA Lt sided, Extensive & Pan UC require oral and topical 5-ASA Meta-analysis (2011) of 11 RCTs Risk of relapse in pts with quiescent UC was lower in pts on 5-ASA vs placebo [RR 0.65, 95% CI 0.55-0.76] Recommended dose to maintain remission ~3-3.6 g/d ECCO guidelines: The minimum effective dose of oral 5- ASA is 1.2 g/day to maintain remission

What are the data on stopping AZA/ 6MP in UC pts? IMM monotx pts who stop the IMM Combotx pts who stop the IMM Now on anti-tnf

What are the data on stopping AZA/ 6MP in UC pts? IMM monotx pts who stop the IMM Combotx pts who stop the IMM Now on anti-tnf

De-escalation of AZA/6MP monotx in UC? Hawthorne et al. -- RCT; 1992 BMJ Lobel et al. -- Retrospective Review; 2004 AJG Fraser et al. -- Retrospective Review; 2002 Gut Cassinotti et al. -- Retrospective Review; 2009 AJG 13

Hawthorne et al. Determine whether AZA prevents relapse in UC 1 yr placebo controlled double blind trial 79 UC outpts on AZA for 6 mths Pts in full remission for 2 mths (clinical & endoscopic) 79 patients 33 AZA cont d 34 placebo 1 yr relapse rate Hawthorne et al. BMJ. 1992; 305(6844): 20-22. 36% 59% P<0.05 14

Retrospective Reviews Cohort studies with very heterogeneous designs and f/u times Relapse rates from: 11% to 77% at 12 months 21% to 100% at 24 months 15

Lobel et al. Retrospective study 61 UC pts on 6MP 6 mths Remission for >3 mths while on 6MP No need for steroids 1-year follow-up 61 patients 39 6MP cont d 22 stopped 6MP 1 yr relapse rate 43% 77% P<0.05 Median time to relapse 58 wks 24 wks P<0.05 2 yr relapse rate 69% 100% P<0.05 Lobel et al. Am J Gastroenterol 2004; 99:462-465. 16

Fraser et al. Retrospective review over a 30-year period factors predicting response to AZA optimal duration of treatment Subgrp of 222 IBD (143 UC; 79 CD) outpt stopped AZA Pts had to be in remission No oral steroids for 3 mths AND Harvey Bradshaw index of <4 Relapse rates defined as active disease requiring steroids or need for a surgical procedure Fraser et al. Gut 2002; 50:485-489. Relapse Rate 1 year 3 years 5 years Off AZA 37% 66% 75% 17

Cassinotti et al. Retrospective observational study Clinical outcomes and predictive factors after withdrawal of AZA in UC 127 UC pts in steroid-free remission >3 mths f/u x 55 months or until relapse Relapse Rate Off AZA 1 year 1/3 3 years 1/2 Cassinotti et al. Am J Gastroenterol 2009; 104:2760-2767. 5 years 2/3 18

Summary Relapse rates were significantly higher in UC pts who stopped 6MP/AZA compared to those who continued treatment After stopping 6MP/AZA average 1-yr relapse rate was 53% (range 35% 77%) by 5 years, relapse rate was 70% (range 65% 75%) 19

What are the data on stopping AZA/6MP in UC pts? IMM monotx pts who dropped the IMM Now on no medications Combotx pts who dropped the IMM Now on anti-tnf

Stopping IMM The only study on stopping IMM after combo tx supported continued IMM use 21

Filippi J et al. Retrospective study IMM withdrawal from combotx Pts in remission 6 mths on combo tx (IFX/AZA) 82 pts with f/u for ~22.3 mths Higher relapse rate in discontinuation cohort 12% vs. 3%; p=0.049 Mean time to relapse 16.6 mths combo vs. 7 mths IFX; p<0.05 22

What are the data on stopping anti- TNF in UC pts?

What are the data on stopping anti- TNF in UC pts? 14 studies described outcomes after anti-tnf withdrawal in UC 5 were retrospective Significant heterogeneity in study design, pt population (proportion of pts on combo ~20-100%), definition of relapse, clinical remission Duration of remission was vague only stated in 2 studies (>6 mths)

What are the data on stopping anti- TNF in UC pts? In adults: 12 month relapse rates: 14% - 41.8% Lower value in pts who had to have mucosal healing prior to de-escalation (17%-25% relapse rate) 24 month relapse rates: 25% - 47.1% Lower value in pts who had to have mucosal healing prior to de-escalation (25%-35% relapse rate)

Putting the data all together. 26

To Date Discontinuation of tx in UC pts needs to be personalized based on preference, disease markers, consequence of relapse, safety & cost IMM and anti-tnf tx should NOT be stopped as long as remission is maintained, cost is not an issue, there are no significant side effects, and the patient is tolerating treatment 27

To Date Further studies are required to accurately identify subgroups of pts who are good candidates for discontinuing tx 28

Question 37 year old male with panuc Diagnosed 10 yrs ago Maintained on AZA and IFX for at least 5 yrs Has been feeling great for the past few years Colonoscopy the last 3 yrs has been normal Random biopsies unremarkable Blood work looks good; CRP normal He is very worried about HSTCL and would like to d/c meds 29

Continue meds? What would you do Continue AZA/stop IFX? Continue IFX/stop AZA? Stop all meds? 30

Question 37 year old male with panuc Diagnosed 10 yrs ago Maintained on AZA and IFX for at least 5 yrs Has been feeling great for the past few years Colonoscopy the last 3 yrs has been normal Random biopsies unremarkable Blood work looks good; CRP normal DEEP REMISSION 31

Question His twin brother: 37 year old male with panuc Diagnosed 10 yrs ago Maintained on AZA and IFX for at least 5 yrs Has been feeling great for the past few years Colonoscopy the last 3 yrs has showed mild erythema Random biopsies with mild colitis Blood work looks good but CRP mildly elevated He is very worried about HSTCL and would like to d/c meds 32

Continue meds? What would you do Continue AZA/stop IFX? Continue IFX/stop AZA? Stop all meds? 33

Question His twin brother: 37 year old male with panuc Diagnosed 10 yrs ago Maintained on AZA and IFX for at least 5 yrs Has been feeling great for the past few years Colonoscopy the last 3 yrs has showed mild erythema Random biopsies with mild colitis Blood work looks good but CRP mildly elevated 34

The WRONG pt to stop meds on Associated with future relapses: - Markers of disease activity - ongoing inflammation on endoscopy - elevated CRP, WBC, etc.. The RIGHT pt to stop meds on..the patient in a deep remission without recent steroid use.. But for how long??? - More extensive disease - Complicated/relapsing disease course - Short duration in remission before d/c tx Associated with reduced relapse rates: - Older age - Longer duration of IMM tx - Biologic remission - Male Gender - Lack of a second concomitant medication; IMM after stopping anti-tnf 35

Torres J et al. Gastroenterology, 2015, Available online 14 September 2015

Synthesis and Consensus: Algorithm from Review article: why, when and how to deescalate therapy in inflammatory bowel diseases Alimentary Pharmacology & Therapeutics Pariente B and Laharie D, 10:338-353, JUN 2014 37

Deep remission Long duration combo tx Mucosal ds Perianal ds Complicated ds Clinical remission Mucosa better, not perfect Short duration combo tx

Thank you 39

Thank you 41